Lovastatin is an irreversible inhibitor of HMG-CoA reductase and blocks the production of mevalonate, a critical compound in the production of cholesterol and isoprenoids. Isoprenylation of target proteins, like the GTP-binding protein Ras, is essential for their membrane localization and subsequent participation in intracellular signaling cascades. Lovastatin effectively decreased the viability of plasma cells from cell lines (n = 10) and myeloma patients' samples (n = 8) in a dose-and time-dependent way. Importantly, co-incubation of lovastatin with dexamethasone had a synergistic effect in inducing plasma cell cytotoxity. This effect was not the consequence of a change in the protein expression levels of Bcl-2 or Bax induced by lovastatin. The decrease in plasma cell viability was the result of induction of apoptosis and inhibition of proliferation. Mevalonate effectively reversed the cytotoxic and cytostatic effects of lovastatin in plasma cells. The cytotoxic activity of lovastatin was higher in Pgp expressing cell lines, but did not correlate with the multidrug resistance (MDR)-related proteins LRP, Bcl-2 and Bax. Lovastatin treatment resulted in a shift of Ras localization from the membrane to the cytosol that was reversed by mevalonate. The data presented in this paper warrant study of lovastatin alone or in combination with therapeutic drugs, in the treatment of myeloma patients.
Introduction
The enzyme 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase catalyzes the reduction of HMG-CoA to mevalonate, which is an intermediate in the synthesis of cholesterol, essential for membrane integrity; of dolichol, required for glycoprotein synthesis; of polyisoprenoids side chains of heme A and ubiquinone, involved in oxidative respiration; and of isopentyl-adenine, present in some tRNAs. Furthermore, mevalonate is also a precursor of the isoprenoids farnesylpyrophosphate and geranylgeranylpyrophosphate. 1 These isoprenoids are used for post-translational modification of a variety of proteins, including Ras and Ras-related GTP binding proteins. Isoprenylation is essential for membrane attachment 2 and participation of the modified proteins in signal transduction processes. [3] [4] [5] [6] [7] Lovastatin is a nonreversible competitive inhibitor of HMGCoA reductase and is widely used for the treatment of hypercholesterolemia. 8 Lovastatin blocks the enzymatic conversion of HMG-CoA to mevalonate and subsequently the synthesis of downstream mevalonate products. In this way lovastatin interferes with isoprenylation and the subsequent membrane localization of G proteins like Ras and Ras-related proteins. 9, 10 Lovastatin inhibits the proliferation of several tumor cells by inducing a growth arrest at the G1/S boundary. 10, 11 Furthermore, lovastatin has a chemosensitizing capacity in cancer [12] [13] [14] [15] [16] [17] [18] and can directly induce apoptosis as has been documented for several tumor cell lines 10, 15, 19, 20 and tumor cells from patients with acute myeloid leukemia, 19 possibly via down-regulation of the anti-apoptotic protein Bcl-2. 15 The observation that long-term treatment of hypercholesterolemia patients with statins was associated with fewer cancer deaths 21 suggests that lovastatin interferes with processes involved in tumorigenesis.
Multiple myeloma is a plasma cell tumor localized in the bone marrow. Although the majority of the patients respond to initial treatment, almost all patients relapse and die from multidrug-resistant disease. Interleukin-6 (IL-6) is the most important growth and survival factor in myeloma. [22] [23] [24] Through binding to the IL-6 receptor, IL-6 activates the JAK-STAT 25 and Ras-MAPK 23 pathways, resulting in proliferation and protection from apoptosis of plasma cells. Activating Ras mutations are associated with IL-6-independent growth 26 and are associated with a dexamethasone and doxorubicin-resistant phenotype. 27 Since lovastatin effectively interferes with the membrane localization of Ras and its subsequent involvement in signaling processes, 20, 28 and knowing the importance of Ras signaling cascades in myeloma, we investigated the ability of lovastatin to induce apoptosis in myeloma cell lines and purified myeloma plasma cells. The results imply that lovastatin alone or in combination with chemotherapeutic drugs might be an effective therapy in multiple myeloma.
Materials and methods

Reagents
Lovastatin was a generous gift from Merck, Sharp & Dohme Research Laboratories (Rahway, NJ, USA) and prepared as described previously. 29 Dexamethasone and mevalonate were purchased from Sigma (St Louis, MO, USA).
Cell lines and culture conditions
Plasma cell lines RPMI-8226 and U266 were obtained from the American Tissue Culture Collection (ATCC) and L363 from the German Collection of Microorganisms and Cell Cultures (GCMC). Plasma cell lines UM-1 and UM-3 were obtained after prolonged in vitro culture of bone marrow aspirates of myeloma patients and have been described before. 30 The plasma cell line UM-6 was obtained under identical conditions as described above. UM-6 cells express high levels of the plasma cell-associated antigens, CD38, CD138 and cytoplasmic lgAkappa, as determined by flow cytometric analysis and immunofluorescence microscopy, respectively. Analysis using ASO-PCR established the clonal relationship between UM-6 and the original myeloma tumor (data not shown). The doxorubicin-resistant cell lines RPMI-DOX40 (DOX40) and RPMI-DOX6 (DOX6) were kind gifts of Dr W Dalton (University of South Florida, Tampa, FL, USA) and Dr R Scheper (Free University, Amsterdam, The Netherlands), respectively. The IL-6-dependent plasma cell line XG-1 (XG-1+) was a kind gift of Dr B Klein (Institute for Molecular Genetics, Montpellier, France). 31 An IL-6-independent variant (XG-1−) was selected by limiting dilution of XG-1+ cells in the absence of IL-6. Cell lines were cultured in RPMI-1640 (GIBCO, Breda, The Netherlands) supplemented with 10% fetal calf serum (FCS) (Integro, Zaandam, The Netherlands), 100 IU/ml penicillin, 100 g/ml streptomycin and 10 M ␤2-mercaptoethanol (growth medium). The IL-6-dependent cell lines XG-1+ and UM-6 were cultured in the continuous presence of exogenous IL-6 (1.25 ng/ml rhIL-6 (Roche, Almere, The Netherlands)) and the RPMI-DOX6 cell line was cultured in the continuous presence of 6 × 10 −8 M doxorubicin. Myeloma plasma cells were purified from mononuclear cells obtained by Ficoll-Paque (Amersham, Pharmacia BiotechAB, Uppsala, Sweden) density centrifugation from bone marrow aspirates of seven myeloma patients and peripheral blood of one patient with primary plasma cell leukemia after obtaining informed consent. The plasma cell percentage in the patient samples varied from 4 to 46% of the mononuclear cells as determined by simultaneous detection of CD38 (anti-CD38-FITC; Immunotech, Marseille, France) and CD138 (anti-CD138-PE; Immunotech) by flow cytometric analysis (FACSCalibur; Becton Dickinson, Erembodegem, Belgium (BDIS)). Myeloma plasma cells were purified ex vivo by magnetic cell sorting (MACS) based on CD138 expression. 32 To this end, mononuclear cells were subsequently labeled with anti-CD138 (Immunotech) and rat anti-mouse IgG1 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and then separated using a high gradient magnetic separation column placed in a strong magnetic field (Miltenyi), exactly following the instructions of the manufacturer. Samples obtained in this way contained Ͼ95% plasma cells as determined by analysis of CD38/CD138 co-expression. For experiments, myeloma cells were resuspended in growth medium (see above).
In vitro cell cultures Viability assay:
Viability of cells was examined by means of the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay as described previously. 33 In short, cells were seeded in a concentration of 0.3 × 10 6 /ml for the plasma cell lines or 1 × 10 6 /ml for the purified myeloma cells and NBM mononuclear cells in a 96-well flat bottom plate (100 l/well) (Nunc, Roskilde, Denmark) and treated with different concentrations lovastatin (0, 1, 5, 10, 20, 40, 60, 80, 100 and 150 M). After 2 or 4 days, 25 l of MTT (5 mg/ml) was added to each well. After an incubation of 2 h at 37°C the reaction was stopped by the addition of 100 l 20% sodium dodecyl sulphate (SDS; Boehringer Mannheim, Mannheim, Germany)/0.025 M HCl/0.35 M HAc in a mixture of (1:1; v/v) N,N-dimethylformamide (Merck, Darmstadt, Germany) and aqua destillata. After an overnight incubation at 37°C the optical density of the samples was determined at 570 nm.
Cell proliferation assay:
Cells ( 34 
Apoptosis assessment by annexin V staining:
Mononuclear cells (3 × 10 5 in 0.5 ml) were incubated with different concentrations lovastatin (0, 5, 10, 40, 100 and 150 M) in a 48-well plate (Nunc). After 2 or 4 days, cells were harvested, washed in ice-cold PBS and directly stained with annexin V-FITC (Nexins Research, Kattendijke, The Netherlands) and propidium iodide (PI). After an incubation for 10 min at 4°C, the cells were subsequently analyzed by flow cytometry as described previously. 30 Apoptotic cells were defined as early apoptotic cells (annexin V positive and PI negative) and late apoptotic cells (annexin V positive and PI positive).
Apoptosis assessment by the TUNEL assay:
Cells were incubated with lovastatin as described above. DNA strand breaks in apoptotic cells were detected by incorporation of FITC-labeled deoxyuridine triphosphate (UTP-FITC) into fragmented DNA by terminal deoxynucleotidyl transferase (TdT) (Boehringer Mannheim). Briefly, cells were subsequently washed in 1% bovine serum albumin (BSA) in PBS at 4°C, fixated in 4% paraformaldehyde solution for 1 h at room temperature, permeabilized in 0.1% Triton X-100 in 0.1% sodiumcitrate solution for 2 min at 4°C and incubated with UTP-FITC and TdT for 1 h at 37°C in the dark. Cells were analyzed by flow cytometry.
Expression of MDR-related proteins
For flow cytometric detection of intracellular Bcl-2, Bax and LRP, cells (0.5-1 × 10 6 ) were fixed and permeabilized using FACS Lysing Solution (FLS, 10% in aqua destillata; BDIS) and subsequently incubated with anti-Bcl-2-FITC (IgG1; Dako, Glostrup, Denmark), anti-Bax (IgG2b; Immunotech) or anti-LRP (IgG2b, a kind gift of Dr R Scheper) antibodies or their isotype and subclass matched control antibodies, followed by incubation with goat anti-mouse IgG F(abЈ) 2 -FITC (Dako) for detection of Bax and LRP. All incubations were performed at room temperature for 30 min except for staining of LRP that was performed at 4°C for 60 min. Between different steps the cells were washed with PBS. Membrane Pgp expression was determined by using the MRK16 antibody (kindly provided by Dr R Scheper) as described before. 33 The mean fluorescence ratio (MFR), defined as the ratio of the mean fluorescence intensities (MFI) of primary antibody and isotype control stained cells was used as a measure for the Bcl-2, Bax, LRP or Pgp protein expression.
Western blotting
Cells (1 × 10 6 cells in 1.5 ml) were incubated for varying lengths of time in growth medium with lovastatin (0, 10 or 30 M) in the presence or absence of 100 M mevalonate. After harvesting, whole cell lysates were made by washing cells twice in ice-cold PBS and then resuspending them in lysis buffer (10 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% Triton X-100 and a cocktail of protease inhibitors (Boehringer Mannheim)) at 4°C for 6 min. Insoluble material was removed by centrifugation at 14000 r.p.m. for 6 min at 4°C. When membrane and cytosolic protein fractions were analyzed, cells were suspended in extraction solution (10% glycerol, 20 mM Hepes, 1 mM MgCl 2 , 1 mM EDTA, 1 mM DTT and a cocktail of protease inhibitors (Boehringer Mannheim)). The lysate was sonificated twice for 5 s and centrifuged at 4°C for 30 min at 48 000 g. The supernatant contained the proteins of the cytosolic fraction. The insoluble material was subsequently resuspended in solubilization buffer (1% NP-40, 20 mM Hepes, 20 mM MgAc, 5 mM NaF, 0.2 mM EDTA, 0.8 mM EGTA, 1 mM DTT and a cocktail of protease inhibitors). After two rounds of sonification for 10 s, an incubation for 30 min at 4°C and a centrifugation step at 4°C for 30 min at 48 000 g, proteins of the membrane fraction were present in the supernatant.
Protein concentrations were determined by the BCA assay (Pierce, Rockford, IL, USA). Samples containing equal amounts of protein were mixed with 2 × Laemmli sample buffer (0.125 M Tris (pH 6.9) with 4% SDS, 20% glycerol and 10% ␤-mercaptoethanol) and boiled for 5 min. Proteins were subsequently fractionated in 10% SDS-PAGE at RT and electrically transferred from the gel to PVDF-membrane (Biorad, Hercules, CA, USA). After blocking in 0.1% Tween-20, 5% skimmed powder milk, 2% BSA in 10 mM Tris and 150 mM NaCl, the membranes were incubated with anti-Bcl-2 (Dako) or anti-Ras (Transduction Laboratories, BDIS). Antibody binding was visualized with enhanced chemoluminescence (Amersham) detection with hyperfilm ECL (Amersham) after incubation with a horseradish peroxidase (HRP)-conjugated secondary antibody (Dako). Membranes incubated with antiBcl-2 or anti-Ras were extensively washed in PBS and reprobed with anti-Bax (Dako) and anti-␣-actin (Sigma) or anti-␥-adaptin (Sigma) and anti-ICAM-1 (clone F7.11 35 
)
, respectively. The level of protein expression was determined by densitometry following normalization for ␣-actin expression.
Statistics
Data analysis was performed using the SPSS statistical software package (SPSS, Chicago, IL, USA). A two-sided Student's t-test or a Welch's t-test in case of unequal variances, was used to determine differences between groups. The correlation between lovastatin sensitivity and MDR-related proteins was calculated by using the Spearman test. Differences and correlations were considered statistically significant when P Ͻ 0.05. Data are plotted as means ± standard error of the mean (s.e.m.).
Results
Lovastatin reduces cell viability in plasma cell lines and in ex vivo purified myeloma plasma cells by inhibition of HMG-CoA reductase
The effect of lovastatin on cell viability was examined on 10 plasma cell lines by using the MTT assay. In vitro incubation with lovastatin decreased cell viability in all plasma cell lines tested in a time-(data not shown) and dose-dependent way, as is shown in Figure 1a for three representative cell lines. The concentration of lovastatin that reduced cell viability of the plasma cell lines with 50% (MTT50) or 75% (MTT25) after 4 days of in vitro culture ranged from 0.8 to 13.3 M (MTT50) Table 1) . Lovastatin inhibits the enzyme HMG-CoA reductase that catalyzes the conversion of 3-hydroxy-3-methyl-glutaryl CoA to mevalonate. To examine whether the reduction in myeloma cell viability was mediated by an inhibition of HMG-CoA reductase activity, we investigated whether mevalonate rescued plasma cells from lovastatin-induced cell death. Co-incubation with mevalonate significantly diminished the effect of lovastatin on plasma cell lines, as shown in Figure 1b for U266 cells.
Myeloma plasma cells were purified from bone marrow aspirates from seven MM patients and peripheral blood from one patient with primary plasma cell leukemia (for clinical data of these patients see Table 2 ) based on CD138 expression using magnetic beads. This isolation method resulted in cell samples that contained Ͼ95% plasma cells (data not shown). Lovastatin also effectively induced tumor cell death in these ex vivo purified myeloma plasma cells in a dose-and timedependent fashion (Figure 2a) . Lovastatin sensitivity differed among the myeloma patients' samples. MTT50 and MTT25 were in the range of 6.0 to 63.4 and 8.9 to Ͼ150 M, respect- 54 The M-protein type was determined by immunofixation. Bone marrow plasma cell percentage was determined by simultaneous detection of CD38 and CD138 in bone marrow mononuclear cells by flow cytometric analysis. Plasma cell monoclonality was established by means of immunofluorescence microscopy based on heavy and light chain expression. MM, multiple myeloma; PCL, plasma cell leukemia; M, male; F, female; Ig, immunoglobulin; autoPBSCT, autologous peripheral blood stem cell transplantation; alloBMT, allogeneic bone marrow transplantation; MP, melphalan and prednisone; VAD, vincristine, doxorubicin and dexamethasone.
ively ( Table 2 ). The reduction of viability of myeloma tumor cells from patients by lovastatin was significantly reversed by co-treatment with mevalonate (shown for cells from patient 5 in Figure 2b ).
Lovastatin induces apoptosis and inhibits proliferation
The effect of lovastatin on plasma cell proliferation and induction of apoptosis was investigated in three plasma cell lines that differed in their lovastatin sensitivity (RPMI-8226, UM-6 and U266). In vitro incubation with lovastatin induced apoptosis in the plasma cell lines in a dose-and time-dependent way, as measured in the annexin V assay (data not shown). The percentage of apoptotic cells was 19.2, 31.9 and 58.2% after 2 days and 32.4, 65.7 and 97.2% after 4 days of incubation with 40 M lovastatin for U266, UM-6 and RPMI-8226 cells, respectively. Mevalonate significantly blocked induction of apoptosis by lovastatin in all three cell lines. Data from a representative experiment performed with UM-6 cells, are shown in Figure 3a . The annexin V data were confirmed Leukemia in an independent flow cytometric apoptosis assay, the Tunel assay (Figure 3b for a representative experiment performed with the RPMI-8226 cell line). The effect of lovastatin on proliferation of RPMI-8226, U266 and UM-6 plasma cell lines was evaluated by measuring 3 H-thymidine incorporation. Figure 4a shows a concentration-dependent decrease of plasma cell proliferation at day 4 in all three cell lines. As with the induction of apoptosis, inhibition of proliferation by lovastatin was significantly abrogated by addition of 100 M mevalonate, as shown in Figure 4b for U266 cells. Thus, these results imply that the effect of lovastatin on plasma cell viability is the consequence of induction of apoptosis and inhibition of proliferation.
Correlation between expression of MDR-related proteins and lovastatin sensitivity
The plasma cell lines differed in their sensitivity to lovastatininduced cell death. Therefore, we investigated a possible correlation between lovastatin sensitivity and IL-6-dependent Effect of lovastatin alone or in combination with mevalonate on viability of ex vivo purified plasma cells. (a) Ex vivo purified myeloma plasma cells from myeloma bone marrow samples (n = 7) and peripheral blood from one patient with primary plasma cell leukemia were incubated for 4 days with different concentrations of lovastatin or solvent control. (b) Purified myeloma tumor cells from patient 5 were incubated with lovastatin for 4 days in the presence or absence of 100 M mevalonate. Cell viability was examined by using the MTT assay as compared with control cells treated with solvent control. Experiments were performed once in triplicate. Data are presented as mean ± s.e.m. *P Ͻ 0.05; **P Ͻ 0.005. growth and expression of the anti-apoptotic protein Bcl-2, the pro-apoptotic protein Bax, the membrane efflux pump Pgp and the human major vault protein LRP (lung resistancerelated protein) in 10 different plasma cell lines. No difference in lovastatin sensitivity was found between IL-6-dependent (XG-1+, UM-6 and U266) and -independent plasma cell lines (Table 1) . Moreover, addition of exogenous IL-6 (5 ng/ml) did not protect against lovastatin-induced cell death (data not shown). All cell lines expressed different levels of intracellular Bcl-2 and Bax, and with the exception of the doxorubicinresistant cell lines RPMI-DOX40 and RPMI-DOX6, the plasma cell lines hardly expressed Pgp and had low or undetectable intracellular LRP expression (Table 1) . There was no significant correlation between Bcl-2, Bax, Bcl-2/Bax-ratio or LRP expression and lovastatin sensitivity. However, lovastatin sensitivity significantly correlated with Pgp expression (r = −0.733 and −0.697; P = 0.016 and 0.025 for MTT50 and MTT25, respectively). Dox6 and Dox40 are doxorubicin-resistant variants of the RPMI-8226 plasma cell line. In these lines doxorubicin resistance positively correlated with the expression of Pgp. The most doxorubicin-resistant cell line (Dox40) was most sensitive for lovastatin treatment, followed by Dox6 and the RPMI-8226.
Dexamethasone synergizes with lovastatin in reducing plasma cell viability
The combined effect of lovastatin and dexamethasone on cell viability was examined by using the MTT assay in three dexamethasone-sensitive plasma cell lines (U266, L363 and XG-1+). In all cell lines, lovastatin had a synergistic effect with dexamethasone in reducing cell viability. A representative experiment with XG-1+ cells is shown in Figure 5 . Dexamethasone (5 M) alone reduced cell viability by 27.5%, lovastatin (1 M) alone by 11.4%, while the combination of both decreased the percentage of viable cells by 54.5%. In the other two cell lines, U266 and L363, a synergistic effect between dexamethasone (0.5 and 5 M) and lovastatin (1-10 M) was found (data not shown).
Lovastatin downregulates Bcl-2 expression only in the U266 cell line
High levels of Bcl-2 protein expression are associated with in vitro resistance to dexamethasone. 36 In colon carcinoma cell lines, lovastatin reduced expression of the anti-apoptotic protein Bcl-2 and increased expression of the pro-apoptotic protein Bax. 15 To determine whether the synergism between dexamethasone and lovastatin in inducing plasma cell cytotoxicity was related to changes in the protein expression of Bcl-2 and Bax by lovastatin, Western blotting was performed. Cells from plasma cell lines (XG-1+, U266 and L363) were incubated for 2 or 4 days with different concentrations of lovastatin in the presence or absence of mevalonate. Lovastatin reduced Bcl-2 protein expression only in U266 cells (shown for day 4 in Figure 6a ), but not in the other two cell lines tested (shown for XG-1+ in Figure 6b ). Bax and ␣-actin levels remained unchanged. Mevalonate prevented lovastatininduced Bcl-2 down-regulation in U266 cells. In two out of eight patients lovastatin treatment resulted in a decreased Bcl-2 protein expression, without changing Bax or ␣-actin expression levels (data not shown).
Lovastatin and protein isoprenylation
Lovastatin depletes the cellular pool of mevalonate by inhibition of HMG-CoA reductase and potentially impairs isoprenylation and a subsequent membrane localization of small GTPases like Ras. The effect of lovastatin on Ras localization was evaluated by incubating U266 cells with different doses of lovastatin in the absence or presence of mevalonate for 2 days. Membrane and cytosol protein fractions were isolated and analyzed by Western blot. In the untreated cells, Ras was predominantly membrane associated ( Figure 7 ). Lovastatin induced a dose-dependent shift of Ras from the membrane to the cytosolic protein fraction. Co-incubation with mevalonate prevented this effect of lovastatin on Ras localization. The localization of non-isoprenylated control proteins, ICAM-1 (membrane protein) and ␥-adaptin (cytosolic protein) was not affected by lovastatin treatment (Figure 7) . Identical results were obtained with the RPMI-8226 and UM-6 plasma cell lines (data not shown). These results show that lovastatin treat-
Figure 3
Lovastatin-induced apoptosis is inhibited by addition of mevalonate, as was determined by two independent apoptosis assays. (a) UM-6 cells were incubated with solvent control, 100 M lovastatin alone or in combination with 100 M mevalonate for 4 days, after which apoptosis was determined by using the annexin V assay. The percentages of viable plasma cells (annexin V−/PI−), early apoptotic cells (annexin V+/PI−) and late apoptotic cells (annexin V+/PI+) in each dot plot are indicated in the corresponding quadrants. (b) RPMI-8226 cells were incubated with solvent control, 100 M lovastatin in the presence or absence of mevalonate (100 M) for 4 days, after which DNA strand breaks were detected by using the TUNEL assay. In the overlay diagram, the filled histogram represents the cells treated with lovastatin alone, the histogram with the bold line the cells treated with mevalonate and lovastatin and the histogram with the thin line cells treated with solvent control. ment of plasma cells impairs membrane localization of Ras, probably via inhibition of isoprenylation.
Discussion
Lovastatin is a HMG-CoA reductase inhibitor, which, because of its inhibition of hepatic cholesterol synthesis, is prescribed as a cholesterol-lowering drug. In this report, we demonstrated for the first time that lovastatin induced cell death in ex vivo purified plasma cells from myeloma patients and cell lines at concentrations that can be achieved in vivo, 37 which was mediated by induction of apoptosis and by inhibition of proliferation. Furthermore, lovastatin in combination with dexamethasone displayed a synergistic effect in inducing cell death.
Lovastatin sensitivity differed among the plasma cell lines and the purified myeloma samples. In plasma cell lines we examined possible correlations between lovastatin sensitivity and IL-6-dependent growth and expression of well-known multiple myeloma multidrug resistance-related proteins 38 such as P-glycoprotein (Pgp), [39] [40] [41] lung resistance protein (LRP) 42, 43 and Bcl-2 family proteins. 36, 44, 45 There was no obvious
Leukemia relationship between IL-6-independent or -dependent plasma cell growth and lovastatin sensitivity. Moreover, addition of exogenous IL-6 did not protect against lovastatin-induced cell death. No correlation was found between lovastatin sensitivity and LRP, Bax or Bcl-2 expression, but cell lines with a high Pgp expression were more sensitive to lovastatin than cell lines, which did not express Pgp. This is in agreement with previously published in vitro studies performed in neuroblastoma, myeloid leukemia and two myeloma cell lines. [46] [47] [48] The correlation between lovastatin sensitivity and Pgp expression indicates that lovastatin can be used for the treatment of myeloma patients with multidrug-resistant disease related to Pgp overexpression.
Induction of apoptosis and inhibition of proliferation of myeloma plasma cells by lovastatin was reversed by addition of mevalonate. Mevalonate is an intermediate in the synthesis of cholesterol, but also of the isoprenoids farnesylpyrophosphate and geranylgeranylpyrophosphate. 1 Ras and Ras-related proteins depend on the covalent attachment of these isoprenoids to their C-terminus for their proper localization to the cell membrane.
2 Plasma membrane localization of Ras is necessary for the conversion of its inactive GDP-to its active GTPbound state, 49 following activation of transmembrane recep- tors by growth factors such as the myeloma growth and survival factor IL-6.
22-24 GTP-bound Ras subsequently activates downstream signaling proteins, which regulate growth and survival. [3] [4] [5] [6] [7] Activating Ras mutations are described in 39% of newly diagnosed myeloma patients 50 and in 64-70% of patients with terminal disease. 24, 51, 52 The presence of Ras mutations at diagnosis is also associated with a poor response to chemotherapy 51 and a shorter survival. 50 In vitro, Ras mutations are associated with IL-6-independent growth and protection from apoptosis induced by IL-6 withdrawal 26 or treatment with dexamethasone and doxorubicin. 27 Importantly, lovastatin inhibits cell proliferation both in cell lines with wild-type and mutant Ras. 53 Our results demonstrate that treatment of plasma cells with lovastatin resulted in a depletion of membrane-localized Ras and an accumulation of cytosolic Ras, probably by inhibition of isoprenylation. This effect was abrogated by mevalonate. The cytotoxic effect of lovastatin on plasma cells may be the consequence of interference with the isoprenylation of Ras and its subsequent involvement in signaling cascades thereby abrogating proliferation and cell survival signals. This is consistent with experiments which show that lovastatin disrupted oncogenic Ras signaling through MAPK, causing apoptosis and inhibiting proliferation. 20, 28 Current experiments focus on the characterization of isoprenylated target proteins that regulate plasma cell survival and proliferation.
In multiple myeloma high levels of the anti-apoptotic protein Bcl-2 are associated in vitro with protection against IL-6-deprived apoptosis 44 and resistance to cytotoxic drugs and dexamethasone. 36 In colon cancer cells lovastatin treatment resulted in a decreased Bcl-2 and an increased Bax protein expression. 15 The results presented in this paper showed that lovastatin and dexamethasone had a synergistic effect in inducing cell death in plasma cell lines. However, lovastatin treatment reduced Bcl-2 protein levels only in the U266 cell line. In L363 and XG-1+ cells, Bcl-2 levels remained unchanged. This implies that although down-regulation of Bcl-2 in U266 cells may contribute to the observed synergistic effect between lovastatin and dexamethasone in the induction of plasma cell cytotoxicity, other mechanisms may account for the synergistic response in the other two cell lines. The same observation was made in ex vivo purified plasma cells; only in two out of eight patients did lovastatin treatment reduce Bcl-2 protein expression, without changing Bax and ␣-actin expression levels.
Serum peak levels in the range of 0.1 to 4 M were achieved in individuals, who received high doses of lovastatin (30 mg/kg/day). These dosages were well tolerated, but as a mono-therapy had little effect in reducing tumor load in patients with solid tumors. 37 However, tumor cells from patients with acute myeloid leukemia (AML) were more sensitive to lovastatin compared to solid tumors. Dosages of lovastatin that are easily reached in vivo, induced cell death of freshly isolated AML cells and decreased the colony-forming potential of AML primary cultures, with minimal effects on normal bone marrow and normal bone marrow progenitors.
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Figure 6
Down-regulation of Bcl-2, but not Bax protein levels in the U266 cell line, which was abrogated by mevalonate. U266 cells were incubated for 4 days with solvent control or 10 or 30 M lovastatin in the presence or absence of 100 M mevalonate. XG-1+ cells were incubated for 4 days with solvent control or the same doses of lovastatin. After protein isolation, Bcl-2 and Bax were determined by Western blot analysis. Blots were reprobed with anti-actin to confirm the presence of equal amounts of protein in each lane. The data presented are representative of three independent experiments.
Figure 7
Lovastatin induces a shift of membrane-associated Ras to cytosol localized Ras, which is abrogated by the addition of mevalonate. U266 cells were incubated with solvent control, 10 or 30 M lovastatin in the presence or absence of 100 M mevalonate. After a 2 day incubation, protein was separated in membrane and cytosolic fractions. Ras was identified by Western blot analysis. The blots were reprobed with anti-ICAM-1 and anti-␥-adaptin, to confirm a well-performed separation and the presence of equal amounts of protein in each lane. The data are representative of three independent experiments.
In this paper, we demonstrate that concentrations that can be achieved in vivo, also effectively killed plasma cell lines and ex vivo purified myeloma tumor cells from patients in vitro. Furthermore, we show that lovastatin at low concentrations (0-10 M) displayed a synergistic effect with dexamethasone in inducing cell death. These results agree with earlier published findings, which show that lovastatin enhanced antitumor activity of several chemotherapeutical agents in solid tumors. [12] [13] [14] [15] [16] [17] [18] In conclusion, lovastatin reduced cell viability in plasma cell lines and ex vivo purified plasma cells from myeloma patients. Dexamethasone synergized with low concentrations of lovastatin in reducing plasma cell viability. Induction of apoptosis in myeloma cell lines by lovastatin was independent of expression of MDR-related proteins like Bcl-2, Bax and LRP, but cells expressing Pgp were more sensitive to lovastatin. Together, our data indicate that lovastatin as a single agent or combined with dexamethasone or dexamethasone containing regimens, should be evaluated in multiple myeloma.
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